Cambridge, MA, United States of America

Tea Shavlakadze

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 7.3

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2020-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Tea Shavlakadze: Innovator in Pharmaceutical Chemistry

Introduction

Tea Shavlakadze is a prominent inventor based in Cambridge, MA, known for his significant contributions to pharmaceutical chemistry. With a total of three patents to his name, he has made strides in the development of innovative compounds that have potential therapeutic applications.

Latest Patents

Shavlakadze's latest patents focus on rapamycin derivatives. The first patent discloses 32-deoxo-rapamycin derivatives of Formula (I), along with pharmaceutically acceptable salts, pharmaceutical compositions, and combinations that utilize these compounds. The methods outlined in this patent aim to treat various diseases and disorders. The second patent also relates to compounds of formula (I) and their pharmaceutically acceptable salts, detailing methods for their synthesis and applications in treating specific disorders.

Career Highlights

Tea Shavlakadze is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on the development of innovative pharmaceutical solutions that address critical health challenges.

Collaborations

Some of his notable coworkers include Simone Bonazzi and David Jonathan Glass, who contribute to the collaborative environment that fosters innovation at Novartis.

Conclusion

Tea Shavlakadze's work in the field of pharmaceutical chemistry, particularly with rapamycin derivatives, showcases his commitment to advancing medical science. His contributions are paving the way for new treatments that could significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…